Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

NCT00667329 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: 2CdA
DRUG: Cyclophosphamide
DRUG: Rituximab

Sponsor

M.D. Anderson Cancer Center